Case presentation - PowerPoint PPT Presentation

1 / 35
About This Presentation
Title:

Case presentation

Description:

... is effective even in patients with normal magnesium levels. ... QT interval by increasing the heart rate and reducing temporal dispersion of repolarization. ... – PowerPoint PPT presentation

Number of Views:270
Avg rating:3.0/5.0
Slides: 36
Provided by: medtr2
Category:

less

Transcript and Presenter's Notes

Title: Case presentation


1
Case presentation
  • Torsade de Pointes

2
C15 Case
  • Mr X presented to ED from Bosbokrandt (Nelspruit
    area) visiting in CPT.
  • He is previously well 28yr old who looks acutely
    ill.
  • History from family
  • General malaise for 7days, Pyrexia (Rigors),
    Deteriorating mental state for past 2 days
    (Confused).
  • No history of trauma, drug abuse or current
    medical problems. He is RVD negative.
  • Noted to be Penicillin allergic. Visited GP 2days
    ago received an antibiotic.

3
Examination
  • Vitals
  • B/P 105/65, H/R 130, Temp 39, R/R 16, GCS 14/15
    (Not orientated), Sats 98 RA
  • Dipstix 1 Blood
  • Glucose 4.5 Hb 9.5
  • Examination
  • Splenomegaly of 2cm noted

4
Special investigations
  • FBC
  • Plasmodium PCR
  • Giemsa stained thick / thin smear
  • CXR
  • LP was deferred until platelet count returned
  • Elected not to CT at this stage

5
Treatment commenced
  • Anti-Malaria treatment was started on clinical
    suspicion and a preliminary positive smear from
    the Lab.
  • Quinine sulphate IV was started as a loading dose
    of 20mg/kg in 5 Dextrose over 4hours.

6
Patient deteriorated 2hours later
  • Pulse rate 180/min with B/P 75/46.
  • GCS 10/15
  • And an ECG that looks like this.

7
ECG
8
Treatment
  • Patient was given Midazolam 5mg IV and was
    cardioverted at 200J Biphasic with return of
    sinus tachycardia.
  • Quinine infusion was stopped and urgent gas was
    done and CEU Magnesium was sent to lab.
  • Later restarted in ICU.

9
Polymorphic VT
10
Polymorphic VT
  • Heart rate Variable
  • Rhythm Irregular
  • Mechanism
  • Reentry
  • Triggered activity
  • Recognition
  • Wide QRS with phasic variation
  • Torsades de pointes

11
Reentrant
  • Reentrant ventricular arrhythmias
  • Premature ventricular complexes
  • Idiopathic left ventricular tachycardia
  • Bundle branch reentry
  • Ventricular tachycardia and fibrillation when
    associated with chronic heart disease
  • Previous myocardial infarction
  • Cardiomyopathy

12
Triggered
  • Triggered activity ventricular arrhythmias
  • Pause-dependent triggered activity
  • Early afterdepolarization (phase 3)
  • Polymorphic ventricular tachycardia
  • Catechol-dependent triggered activity
  • Late afterdepolarizations (phase 4)
  • Idiopathic right ventricular tachycardia

13
Triggered
Fogoros Electrophysiologic Testing. 3rd ed.
Blackwell Scientific 1999 158.
14
Sustained vs. Nonsustained
  • Sustained VT
  • Episodes last at least 30 seconds
  • Commonly seen in adults with prior
  • Myocardial infarction
  • Chronic coronary artery disease
  • Dilated cardiomyopathy
  • Non-sustained VT
  • Episodes last at least 6 beats but lt 30 seconds

15
Torsades de Pointes (TdP)
  • Heart rate 200 - 250 bpm
  • Rhythm Irregular
  • Recognition
  • Long QT interval
  • Wide QRS
  • Continuously changing QRS morphology

16
Causes
  • Congenital long QT syndromes (adrenergic-dependent
    )
  • Jervell and Lange-Nielsen syndrome
  • Acquired long QT syndromes
  • Antiarrhythmic drugs
  • Class 1A - Quinidine, disopyramide, procainamide
  • Class III - Sotalol, amiodarone (rare),
    ibutilide, dofetilide, almokalant
  • Histamine1-receptor antagonists - Terfenadine,
    astemizole
  • Cholinergic antagonists - Cisapride,
    organophosphates (pesticides)
  • Antibiotics - Erythromycin, clarithromycin,
    trimethoprim-sulfamethoxazole, clindamycin,
    pentamidine, amantadine, chloroquine,
    halofantrine
  • Electrolyte abnormalities - Hypokalemia,
    hypomagnesemia, hypocalcemia

17
Pathophysiology
  • The association between torsade and a prolonged
    QT interval has long been known, but the
    mechanisms involved at the cellular and ionic
    levels have been made clearer in approximately
    the last decade.

18
Pathophysiology
19
Phases
20
Phase 1
  • Phase 1 During initial upstroke of action
    potential in a normal cardiac cell, a rapid net
    influx of positive ions (Na and Ca) occurs,
    which results in the depolarization of the cell
    membrane. This is followed by a rapid transient
    outward potassium current (Ito), while the influx
    rate of positive ions (Na, Ca) declines. This
    represents the initial part of the
    repolarization, or phase 1.

21
Phase 2
  • Phase 2 is characterized by the plateau, the
    distinctive feature of which is the cardiac
    repolarization. The positive currents flowing
    inward and outward become almost equal during
    this stage.

22
Phase 3
  • Phase 3 of the repolarization is mediated by
    activation of the delayed rectifier potassium
    current (IK) moving outward while the inward
    positive current decays. If a slow inactivation
    of the Ca and Na currents occurs, this inward
    "window" current can cause single or repetitive
    depolarization during phases 2 and 3 (ie, EADs).
    These EADs appear as pathologic U waves on a
    surface ECG, and, when they reach a threshold,
    they may trigger ventricular tachyarrhythmias.

23
ECG Recognition
EGM used with permission of Texas Cardiac
Arrhythmia, P.A.
24
ECG changes
  • Patients have paroxysms of 5-20 beats, with a
    heart rate faster than 200 bpm sustained
    episodes occasionally can be seen.
  • Progressive change in polarity of QRS about the
    isoelectric line occurs.
  • Complete 180 twist of QRS complexes in 10-12
    beats is present.
  • Usually, a prolonged QT interval and pathological
    U waves are present, reflecting abnormal
    ventricular repolarization. The most consistent
    indicator of QT prolongation is a QT of 0.60 s or
    longer or a QTc (corrected for heart rate) of
    0.45 s or longer.
  • A short-long-short sequence between the R-R
    interval occurs before the trigger response.

25
ECG Long QT
  • Marked QT prolongation in an asymptomatic patient
    on erythromycin. Patient also was found to be
    profoundly hypomagnesemic and hypokalemic.

26
ECG
  • This shows an example of recurrent nonsustained
    torsade de pointes that occurred several hours
    after the ECG was performed. With discontinuation
    of the erythromycin and aggressive repletion of
    the magnesium and potassium, no further torsade
    de pointes occurred and the patient's QT interval
    returned to normal.

27
Mechanism
  • Events leading to TdP are
  • Hypokalemia
  • Prolongation of the action potential duration
  • Early afterdepolarizations
  • Critically slow conduction that contributes to
    reentry

28
ECG Recognition
  • QRS morphology continuously changes
  • Complexes alternates from positive to negative

29
Treatment
  • Pharmacologic therapy
  • Potassium
  • Magnesium
  • Isoproterenol
  • Possibly class Ib drugs (lidocaine) to decrease
    refractoriness/shorten length of action potential
  • Overdrive ventricular pacing
  • Cardioversion

30
Overdrive pacing
31
Treatment
  • Discontinuation of the offending agent. Any
    offending agent should be withdrawn.
    Predisposing conditions such as hypokalemia,
    hypomagnesemia, and bradycardia should be
    identified and corrected.

32
Treatment
  • Suppression of early after depolarizations.Magne
    sium is the drug of choice for suppressing EADs
    and terminating the arrhythmia.This is achieved
    by decreasing the influx of calcium, thus
    lowering the amplitude of EADs. Magnesium can
    be given at 1-2 g IV initially in 30-60 seconds,
    which then can be repeated in 5-15 minutes.
    Alternatively, a continuous infusion can be
    started at a rate of 3-10 mg/min. Magnesium is
    effective even in patients with normal magnesium
    levels.

33
Treatment
  • Isoproterenol This drug can be used in
    bradycardia-dependent torsade that usually is
    associated with acquired long QT syndrome
    (pause-dependent). It should be administered as
    a continuous IV infusion to keep the heart rate
    faster than 90 bpm. Isoproterenol accelerates AV
    conduction and decreases the QT interval by
    increasing the heart rate and reducing temporal
    dispersion of repolarization. Beta-adrenergic
    agonists are contraindicated in the congenital
    form of long QT syndrome (adrenergic-dependent).

34
New ACLS Algorithm
35
END
Write a Comment
User Comments (0)
About PowerShow.com